scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
35 hedge funds and large institutions have $22.5M invested in scPharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 6 closing their positions.
1.98% less ownership
Funds ownership: 42.26% → 40.28% (-2%)
3% less funds holding
Funds holding: 36 → 35 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
24% less capital invested
Capital invested by funds: $29.5M → $22.5M (-$7.05M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$172K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$81.4K |
| 3 |
SG Americas Securities
New York
|
+$58.4K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$58.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$666K |
| 2 |
AIC
AWM Investment Company
New York
|
-$575K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$131K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$73.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$67K |
SCPH Hedge Fund Activity: Q1 2019 in Review
35 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2019, worth a combined $22.5M — down 24% from $29.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SCPH and 5 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 7 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $172K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $666K sold.
- 35 institutional investors held scPharmaceuticals (SCPH) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $22.5M of scPharmaceuticals stock for Q1 2019, down 24% quarter-over-quarter.
- 5 funds opened new scPharmaceuticals positions in Q1 2019 and 6 closed out, a net change of -1 holder.
- The largest scPharmaceuticals buyer in Q1 2019 was Bridgeway Capital Management, an estimated $172K added.
- The largest scPharmaceuticals seller in Q1 2019 was Alyeska Investment Group, an estimated $666K sold.
Based on aggregated 13F filings for Q1 2019.